Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb;52(3):796-800.
doi: 10.1007/s00259-024-07020-1.

Identifying and navigating bottlenecks in the translation of novel radiopharmaceuticals: a perspective

Margret Schottelius  1   2
Affiliations
Editorial

Identifying and navigating bottlenecks in the translation of novel radiopharmaceuticals: a perspective

Margret Schottelius. Eur J Nucl Med Mol Imaging. 2025 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards. Ethical approval: Not applicable to this Editorial. Informed consent: Not applicable. Conflict of interest: The author declares no conflicts of interest.

References

    1. Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, et al. Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:597–610. - PMC - PubMed
    1. Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752–63. - PubMed
    1. Cui XY, Li Z, Kong Z, Liu Y, Meng H, Wen Z, et al. Covalent targeted radioligands potentiate radionuclide therapy. Nature. 2024;630:206–13. - PubMed
    1. Martin S, Wendlinger L, Zitti B, Hicham M, Postupalenko V, Marx L, et al. Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation. EJNMMI Res. 2024;14:77. - PMC - PubMed
    1. Beauregard JM. Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer. Cancer Imaging. 2022;22:67. - PMC - PubMed

Publication types

LinkOut - more resources